amikacin has been researched along with achn 490 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aggen, JB; Armstrong, ES; Bonomo, RA; Choudhary, Y; Endimiani, A; Hujer, AM; Hujer, KM | 1 |
| Aggen, JB; Armstrong, ES; Diokno, R; Dozzo, P; Feeney, LA; Gliedt, MJ; Goldblum, AA; Gomez, M; Hildebrandt, DJ; Kubo, A; Linsell, MS; Lopez, S; Matias, RD; Miller, GH; Moser, HE; Wlasichuk, KB | 1 |
| Adam, H; Findlay, B; Gin, AS; Hoban, DJ; Karlowsky, JA; Lawson, CD; Lynch, JP; Rubinstein, E; Schweizer, F; Walkty, A; Zelenitsky, S; Zhanel, GG | 1 |
| Argyropoulou, A; Chrysouli, Z; Daikos, GL; Galani, I; Giamarellou, H; Panagea, T; Petrikkos, G; Plakias, G; Poulakou, G; Psichogiou, M; Souli, M; Stefanou, I | 1 |
| Almaghrabi, R; Chen, L; Clancy, CJ; Doi, Y; Hao, B; Iovine, NM; Kreiswirth, B; Nguyen, MH; Press, EG; Shields, RK; Townsend, BM; Wagener, MM | 1 |
| Culebras, E; García-Salguero, C; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Alkroud, A; Cheng, S; Churilla, BM; Churilla, TM; Clancy, CJ; Doi, Y; Haidar, G; Nguyen, MH; Shields, RK | 1 |
| Bush, K; Kashikar, A; Zhang, Y | 1 |
| Bail, L; da Silva Nogueira, K; Dalmolin, TV; Ito, CAS; Martins, AF; Martins, AS; Rocha, JLL; Serio, AW; Tuon, FF | 1 |
| Kidd, JM; Kuti, JL; Nicolau, DP | 1 |
| Attwood, M; Bowker, KE; Kim, A; Krause, KM; MacGowan, AP; Noel, AR | 1 |
| Burgess, DS; Clark, JA; Kulengowski, B | 1 |
| Nambiar, S; Schumann, K; Walinsky, S | 1 |
| Arya, DP; Bassenden, AV; Berghuis, AM; Blanchet, J; Dumalo, L; Maiti, K; Park, J | 1 |
| Bakkaloglu, Z; Demirbas, Z; Dizbay, M; Ozger, HS; Suzuk-Yildiz, S | 1 |
2 review(s) available for amikacin and achn 490
| Article | Year |
|---|---|
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Topics: Amikacin; Aminoglycosides; Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2012 |
Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Pneumonia, Ventilator-Associated; Sisomicin | 2018 |
13 other study(ies) available for amikacin and achn 490
| Article | Year |
|---|---|
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Structure | 2009 |
Synthesis and spectrum of the neoglycoside ACHN-490.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Enterobacteriaceae; Microbial Sensitivity Tests; Molecular Structure; Proteus mirabilis; Pseudomonas aeruginosa; Sisomicin | 2010 |
Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Gentamicins; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin; Tertiary Care Centers; Tobramycin | 2012 |
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enzyme Assays; Gene Expression; Gentamicins; Isoenzymes; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin | 2014 |
Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Cross Infection; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2015 |
Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biotransformation; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Gene Expression; Gentamicins; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2016 |
In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Indiana; Klebsiella pneumoniae; Methyltransferases; Microbial Sensitivity Tests; Sisomicin | 2017 |
Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenem-Resistant Enterobacteriaceae; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Sisomicin; Thienamycins | 2018 |
Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin | 2019 |
In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2020 |
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |
Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes.
Topics: Acetyltransferases; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Binding Sites; Cloning, Molecular; Crystallography, X-Ray; Drug Resistance, Bacterial; Escherichia coli; Gene Expression; Genetic Vectors; Humans; Kinetics; Models, Molecular; Netilmicin; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Providencia; Recombinant Proteins; Sisomicin; Substrate Specificity; Tobramycin | 2021 |
In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Gentamicins; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sisomicin; Tobramycin | 2022 |